[Clinical reports on the treatment with cefazolin for urogenital organ infection (author's transl)].
D000208:Acute Disease; D000328:Adult; D000367:Age Factors; D000368:Aged; D001419:Bacteria / Q000187:drug effects / Q000302:isolation & purification; D001424:Bacterial Infections / Q000188:drug therapy*; D001835:Body Weight; D002511:Cephalosporins / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003556:Cystitis / Q000188:drug therapy; D004823:Epididymitis / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy; D011704:Pyelonephritis / Q000188:drug therapy; D013440:Sulfides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D013777:Tetrazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D013830:Thiadiazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014570:Urologic Diseases / Q000188:drug therapy* / Q000382:microbiology
D002511:Cephalosporins; D013440:Sulfides; D013777:Tetrazoles; D013830:Thiadiazoles